Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 111

Similar articles for PubMed (Select 21958585)

1.

Mepolizumab, a humanized anti-IL-5 mAb, as a treatment option for severe nasal polyposis.

Gevaert P, Van Bruaene N, Cattaert T, Van Steen K, Van Zele T, Acke F, De Ruyck N, Blomme K, Sousa AR, Marshall RP, Bachert C.

J Allergy Clin Immunol. 2011 Nov;128(5):989-95.e1-8. doi: 10.1016/j.jaci.2011.07.056. Epub 2011 Sep 28.

PMID:
21958585
2.

Nasal IL-5 levels determine the response to anti-IL-5 treatment in patients with nasal polyps.

Gevaert P, Lang-Loidolt D, Lackner A, Stammberger H, Staudinger H, Van Zele T, Holtappels G, Tavernier J, van Cauwenberge P, Bachert C.

J Allergy Clin Immunol. 2006 Nov;118(5):1133-41. Epub 2006 Sep 26.

PMID:
17088140
4.

Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody.

Smith DA, Minthorn EA, Beerahee M.

Clin Pharmacokinet. 2011 Apr;50(4):215-27. doi: 10.2165/11584340-000000000-00000. Review.

PMID:
21348536
5.

Preclinical efficacy and safety of mepolizumab (SB-240563), a humanized monoclonal antibody to IL-5, in cynomolgus monkeys.

Hart TK, Cook RM, Zia-Amirhosseini P, Minthorn E, Sellers TS, Maleeff BE, Eustis S, Schwartz LW, Tsui P, Appelbaum ER, Martin EC, Bugelski PJ, Herzyk DJ.

J Allergy Clin Immunol. 2001 Aug;108(2):250-7.

PMID:
11496242
6.

Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.

Straumann A, Conus S, Grzonka P, Kita H, Kephart G, Bussmann C, Beglinger C, Smith DA, Patel J, Byrne M, Simon HU.

Gut. 2010 Jan;59(1):21-30. doi: 10.1136/gut.2009.178558. Epub .

PMID:
19828470
7.

Mepolizumab and exacerbations of refractory eosinophilic asthma.

Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, Marshall RP, Bradding P, Green RH, Wardlaw AJ, Pavord ID.

N Engl J Med. 2009 Mar 5;360(10):973-84. doi: 10.1056/NEJMoa0808991. Erratum in: N Engl J Med. 2011 Feb 10;364(6):588.

8.

An antibody against IL-5 reduces numbers of esophageal intraepithelial eosinophils in children with eosinophilic esophagitis.

Assa'ad AH, Gupta SK, Collins MH, Thomson M, Heath AT, Smith DA, Perschy TL, Jurgensen CH, Ortega HG, Aceves SS.

Gastroenterology. 2011 Nov;141(5):1593-604. doi: 10.1053/j.gastro.2011.07.044. Epub 2011 Aug 9.

PMID:
21835135
9.

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.

Nair P, Pizzichini MM, Kjarsgaard M, Inman MD, Efthimiadis A, Pizzichini E, Hargreave FE, O'Byrne PM.

N Engl J Med. 2009 Mar 5;360(10):985-93. doi: 10.1056/NEJMoa0805435.

10.

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.

Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, Ortega H, Chanez P.

Lancet. 2012 Aug 18;380(9842):651-9. doi: 10.1016/S0140-6736(12)60988-X.

PMID:
22901886
11.

Inhibition of interleukin-5 for the treatment of eosinophilic diseases.

Corren J.

Discov Med. 2012 Apr;13(71):305-12. Review.

12.

[Polyposis nasi--improvement in quality of life by the influence of leukotrien receptor antagonists].

Pauli C, Fintelmann R, Klemens C, Hilgert E, Jund F, Rasp G, Hagedorn H, Kramer MF.

Laryngorhinootologie. 2007 Apr;86(4):282-6. Epub 2007 Feb 8. German.

PMID:
17286243
13.

Clinical significance of eosinophilic cationic protein levels in nasal secretions of patients with nasal polyposis.

Sun DI, Joo YH, Auo HJ, Kang JM.

Eur Arch Otorhinolaryngol. 2009 Jul;266(7):981-6. doi: 10.1007/s00405-008-0872-9. Epub 2008 Nov 26.

PMID:
19034473
14.

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

Garrett JK, Jameson SC, Thomson B, Collins MH, Wagoner LE, Freese DK, Beck LA, Boyce JA, Filipovich AH, Villanueva JM, Sutton SA, Assa'ad AH, Rothenberg ME.

J Allergy Clin Immunol. 2004 Jan;113(1):115-9. Epub 2003 Dec 12.

PMID:
14699394
15.

A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.

Busse WW, Ring J, Huss-Marp J, Kahn JE.

J Allergy Clin Immunol. 2010 Apr;125(4):803-13. doi: 10.1016/j.jaci.2009.11.048. Review.

PMID:
20371394
16.
17.

Mepolizumab and eosinophil-mediated disease.

Walsh GM.

Curr Med Chem. 2009;16(36):4774-8. Review.

PMID:
19929788
18.

A randomized controlled trial of mometasone furoate nasal spray for the treatment of nasal polyposis.

Stjärne P, Mösges R, Jorissen M, Passàli D, Bellussi L, Staudinger H, Danzig M.

Arch Otolaryngol Head Neck Surg. 2006 Feb;132(2):179-85.

PMID:
16490876
20.

Inflammatory mediators and eosinophilia in atopic and non-atopic patients with nasal polyposis.

Scavuzzo MC, Fattori B, Ruffoli R, Rocchi V, Carpi A, Berni R, Giambelluca MA, Giannessi F.

Biomed Pharmacother. 2005 Jul;59(6):323-9.

PMID:
15935609
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk